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Insulin-like growth factor 1 (IGF-1) mediates many of
the actions of growth hormone. Overexpression of
IGF-1 has been reported to have endocrine and para-
crine/autocrine effects on somatic growth in trans-
genic mice. To study the paracrine/autocrine effects
of IGF-1 in hair follicles, transgenic mice were pro-
duced by pronuclear microinjection of a construct
containing a mouse ultra-high sulfur keratin (UHS-
KER) promoter linked to an ovine IGF-1 cDNA. This
UHS-KER promoter has previously been shown to
direct expression of a reporter gene to the hair follicles
of transgenic mice. Four transgenic mouse lines were
established as a result of microinjection of 435
embryos. Transgene expression was found in skin at
day 8 and day 15 of age in three of the lines. Progeny
tests were carried out by mating two of the transgenic
The growth of mouse vibrissae is a cyclic process inwhich every follicle proceeds from a growing phase(anagen), through a regression phase (catagen), to aresting phase (telogen). All individual follicles haveregular, predictable and relatively short growth cycles
that are useful properties for both in vivo and in vitro studies
(Robinson et al, 1997). The first neonatal growth cycle begins at
about 3 d after birth and the length of the vibrissae increases by a
constant amount each day until about 22 d of age (Ibrahim and
Wright, 1975).
The role of insulin-like growth factor 1 (IGF-1) in hair fiber
growth is still not completely understood. Plasma IGF-1 mediates
endocrine effects of growth hormone (GH) on somatic growth
while locally produced IGF-1 has both autocrine and paracrine
actions on tissue growth (D’Ercole et al, 1984). In the skin,
fibroblast-derived IGF-1 has paracrine effects on the proliferation
of keratinocytes (Barreca et al, 1992) and in cultured follicles it is
capable of stimulating human hair growth (Philpott et al, 1994).
Mice transgenic for IGF-1 and a metallothionein (MT) promoter
were reported to have both endocrine and autocrine/paracrine
effects on somatic growth (Mathews et al, 1988; Behringer et al,
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expressing males to nontransgenic females. Mice from
one line were all nonexpressors while four of the 12
mice from the other showed integration of the trans-
gene and three expressed transgene IGF-1 mRNA in
the skin. Vibrissa growth at 11–21 d of age was
significantly greater in transgenic expressors than in
their nontransgenic littermates. Specifically, the
increase in vibrissa length for transgenics at days 11–
16 (20.5%) is µ2-fold compared with days 16–21
(11.9%). These results demonstrate that local over-
expression of IGF-1 in transgenic mice is capable of
stimulating vibrissa growth during the first neonatal
hair cycle. Key words: insulin-like growth factor 1 (IGF-1)
transgenic mice/endocrine, paracrine and autocrine/neonatal
hair cycle/vibrissa growth. J Invest Dermatol 112:245–248,
1999
1990). IGF-1 is expressed in rat and human hair follicles (Messenger,
1989; Little et al, 1994b) and we previously have detected its
mRNA in sheep skin by ribonuclease protection assay (Damak
et al, 1996b). Although these results support the important role of
locally produced IGF-1 in hair growth, Sutton et al (1995) did not
find IGF-1 mRNA in the skin of fetal sheep using reverse
transcription–polymerase chain reaction (PCR) amplification.
To study the local effect of IGF-1 on vibrissa growth, transgenic
mice driven by a mouse hair keratin promoter (McNab et al, 1990)
were produced in our laboratory. Using this promoter we have
previously demonstrated an increase in wool production in trans-
genic sheep (Damak et al, 1996b). In this paper, we report the
results of vibrissa elongation during the initial hair cycle in
transgenic mice.
MATERIALS AND METHODS
Animals Swiss random white (SRW) mice were purchased from the
Animal Breeding Station, Mosgiel, NZ and used as embryo donors
and recipients. At birth, a tail biopsy was taken from each mouse for
DNA analysis.
Transgene constructs Transgenic mice were made by pronuclear
microinjection of a pKER-IGF-1 gene construct as previously described
(Damak et al, 1996b). The KER-IGF-1 DNA construct was made by
ligating an ovine IGF-1 (oIGF-1) cDNA (Wong et al, 1989) downstream
from the mouse ultra-high sulfur keratin (UHS-KER) gene promoter
(McNab et al, 1990).
Screening for transgene integration Mice born from microinjected
embryos were tested for integration of the transgene by Southern blotting.
Genomic DNA was extracted from tail biopsies taken shortly after birth
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according to the methods described by Sambrook et al (1989). The extracted
DNA was digested with appropriate restriction enzymes, separated on a
0.8% agarose gel electrophoresis and a Southern transfer performed as
described by Sambrook et al (1989). The oIGF-1 cDNA was random-
prime labeled with 32P using the Megaprime DNA labeling systems
(Amersham, Bucks, U.K.) according to the manufacturer’s instructions.
Hybridization was performed with the oIGF-1 DNA probe labeled to a
specific activity of 108 dpm per µg.
Analysis of transgene expression Total RNA was extracted from
mouse skin biopsies at 8 d (mid-anagen) and 15 d (late-anagen) of age
using Trizol solution (Life Technologies, Gaithersburg, MD) according to
the manufacturer’s directions. Mice showing integration of the transgene
were tested for expression of IGF-1 mRNA by ribonuclease protection
assay (RPA) using a commercial kit (Ambion, Austin, TX). The DNA
template used in RPA was prepared as previously described by Damak et al
(1996b) The riboprobe contains 200 bp of the IGF-1 and 87 bp of vector
sequences, which allowed the detection of a 287 bp band representing the
transgenic message. RPA was accomplished by mixing 20 µg total RNA
with 105 cpm 32P-riboprobe according to the instructions from the
Ambion kit.
Progeny testing IGF-1 transgenic mice were produced by mating a
transgenic SRW male expressing IGF-1 mRNA in the skin with a
nontransgenic female. Food and water were provided ad libitum and
fluorescent lighting from 5:00 am to 7:00 pm each day. At the birth of
offspring, the sire was removed from the cage and the female kept in the
same cage as the offspring throughout the trial. PCR was used to verify
that offspring carried the IGF-1 transgene DNA in their genomes. DNA
from mouse tails collected at 22 d of age was extracted as previously
described and dissolved in TE buffer. This genomic DNA was mixed with
0.05 µM of each primer KER (59-TCCTGCTTATTGGTCCCTT-39) and
IGF-1 (59-AGGGCCAGATAGAAGAGATG-39) (synthesized by Oligos,
Philadelphia, MA), 0.2 µM each of dATP, dTTP, dCTP, and dGTP, 1 3
amplification buffer (10 mM Tris pH 8.3, 50 mM KCl, 2.5 mM MgCl2)
and 1 unit of Taq DNA polymerase (Promega, Madison, WI) in 50 µl
reactions. Amplification of DNA was achieved by 30 cycles of 94°C for
1 min, 55°C for 2 min, 72°C for 2.5 min, followed by 72°C for 7 min.
Amplimers were analyzed using 1% agarose gel electrophoresis to determine
whether the 350 bp UHS-KER-IGF-1 fragment was present. Total RNA
extracted from skin biopsies of mice at day 22 was tested for expression of
the transgene by RPA as previously described.
Measurement of vibrissa length The incorporation of labeled cystine,
as previously used to measure the rate of wool growth (Wynn et al, 1988),
was applied to the measurement of mouse vibrissa length. At 11, 16, and
21 d of age each mouse received a single, intraperitoneal injection of
0.25 µCi 35S-L-cystine (specific activity 250 mCi per mM, Amersham) in
0.1 ml 0.9% (wt/vol) NaCl. Vibrissae were taken 24 h after the last
injection, placed on microscope slides, coated with 5% (wt/vol) egg
albumin, covered with photographic emulsion (Hypercoat Emulsions,
Amersham), exposed at 4°C and developed 6 wk after exposure. Images of
the fibers were projected at constant magnification through a photographic
enlarger (Durst 300, Durst, Milan, Italy). The length between spots
representing the first and second (days 11–16) and second and third (days
16–21) 35S injections was measured with a planimeter to assess elongation
during that period.
Statistical analysis Inter-mouse variation was used to calculate the
error of analysis of vibrissa elongation. Mean vibrissa length was calculated
for each mouse at two different time periods (days 11–16 and 16–21) and
the total period (days 11–21). The data were analyzed using the statistical
program SYSTAT for Windows, Version 51992 (SYSTAT, Chicago, IL)
running on a personal computer. Data arising from measurement of vibrissa
length at days 11–16, 16–21, and 11–21 were subjected to analysis of
covariance (ANCOVA) using body weight on day 22 as the covariate, to
compare transgenic and nontransgenic mice. Data arising from measure-
ments of body weight on day 22 were subjected to analysis of variance
(ANOVA) to test effects of transgene expression.
RESULTS
Transgene integration Microinjection and transfer of 435
embryos resulted in 40 mice being born, of which four were
transgenic, 1377, 1417, 1453, and 1455, as determined by Southern
blot analysis. Transgenesis was assessed by the presence of a 700 bp
band that is not detectable in nontransgenic mouse DNA and each
Figure 1. Analysis of transgenic status by PCR in IGF-1 transgenic
mice. Genomic DNA was extracted from mouse tails and amplified by
PCR as outlined in Materials and Methods. Lane 1, a molecular weight size
marker, lambda DNA digested with HindIII; lanes 2–13, DNA from 12
transgenic mice of line 1417 after PCR amplification and four (lanes 5, 6,
8, and 11) showed 350 bp UHS-KER-IGF-1 fragments; lane 14, DNA
from one nontransgenic mouse of line 1377; lane 15, DNA from one
nontransgenic mouse of line 1455; lane 16, DNA from one transgenic
mouse of line 1455 and the 350 bp fragment is shown.
of the four transgenic mice had µ5–10 unrearranged copies of the
transgene (data not shown).
Gene expression Transgene expression was found in skin at
day 8 and day 15 of age in lines 1417, 1453, and 1455 as determined
by RPA (data not shown). As the mice from line 1453 failed to
produce offspring, further analysis for transgenic status and gene
expression was performed from lines 1417 and 1455. Four of 12
mice from the same litter of line 1417 were transgenic as determined
by PCR (Fig 1) and transgene expression was shown in the skin
of three transgenic mice by RPA (Fig 2). As mice from line 1455
were all nonexpressors (data not shown), they were excluded from
the analysis of vibrissa growth.
Vibrissa elongation Incorporation of 35S-cystine into vibrissae
from one of the transgenic mice from line 1417 is shown in Fig 3.
Measurements were obtained on 10–15 vibrissae per mouse from
both transgenic and nontransgenic groups. As there was only one
mouse that was a nonexpressor in the transgenic group, analysis of
vibrissa elongation for this mouse relative to those from other
groups was not performed. Vibrissa elongation was compared
between transgenic expressors and nontransgenics as shown in
Table I. Overexpression of IGF-1 in transgenic expressors had
significant (p , 0.05) effect on vibrissa elongation at days 11–21.
The increase in length is µ16.6% compared with nontransgenics
(Table I). Vibrissa elongation in transgenics was also significantly
(p , 0.05) increased compared with nontransgenics in two separate
time periods: days 11–16 and days 16–21. The increase for
transgenics over days 11–16 is µ20.5% and days 16–21, 11.9%
(Table I).
Body weight Transgenic expressors did not differ (p . 0.05)
from nontransgenics in body weight on day 22 of mouse age
(Table I).
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Figure 2. Analysis of IGF-1 mRNA expression in the skin of mice
from line 1417 by RPA. RPA was accomplished by hybridization of
total RNA extracted from mouse skin with a radioactively labeled anti-
sense IGF-1 riboprobe. The ovine IGF-1 probe protected a 287 bp
fragment (lanes 6–8 and 10) corresponding to mRNA transcribed from the
transgene (IGF-1 and vector) as described in Materials and Methods. Lane
1, partially degraded IGF-1 probe, which may be due to radiolytic decay;
lane 2, a 330 nt mouse actin probe was prepared by in vitro transcription
of a 250 bp mouse β-actin DNA (provided with the RPA kit, Ambion)
by T7 RNA polymerase according to the methods described in SP6/T7
Transcription Kit, Boehringer (Mannheim, Germany); lane 3, a 250 bp
fragment corresponding actin message was protected by actin probe and
detected in mouse liver; lane 4, some background is shown on the
hybridization of IGF-1 probe with yeast RNA and this probably due to
incomplete digestion of the probe by RNase; lane 5, blank lane; lanes 6–
9, IGF-1 probe hybridized with transgenic mouse skin RNA from line
1417; lane 10, IGF-1 probe hybridized with mouse skin RNA from one
expressor of line 1453.
Figure 3. Measurement of vibrissa growth at days 11–16 and 16–21
of age in one of the transgenic line 1417 mice using 35S-cystine
incorporation into hair fibers. Three spots (from top) represent
incorporation of 35S-cystine into fibers of mouse vibrissae at days 11, 16,
and 21 of age.
Table I. Vibrissa growth and body weight of transgenic expressors and nontransgenics on days 11–22 of mouse age
Vibrissa growth (mm)a
Body weight (g)a
Status No. mice No. vibrissa days 11–16 days 16–21 days 11–21 day 22
TG Expb 3 40 4.05 6 0.35 4.33 6 0.24 8.38 6 0.58 10.24 6 1.01
NTGc 8 104 3.36 6 0.26 3.87 6 0.33 7.22 6 0.59 9.56 6 1.91
Significanced p , 0.05 p , 0.05 p . 0.05 p , 0.05
aMean 6 SD.
bTransgenic expressors.
cNon-transgenics.
dThe value of significance was shown as p , 0.05 using ANCOVA for vibrissa growth and ANOVA for body weight.
DISCUSSION
We previously reported increased fleece weights during yearling
shearing in IGF-1 transgenic sheep compared with their nontrans-
genic half-sibs (Damak et al, 1996b). In this paper, we report increased
vibrissa length during the first neonatal hair cycle in transgenic mice
compared with their littermates. The influence of IGF-1 on hair fiber
growth in these transgenic animals may therefore be both increased
fiber length and fiber weight. Further, our results demonstrated
that, using 35S-cystine, the length of vibrissa growth in mice can be
determined by directly measuring the radioactively labeled spots
being incorporated into the hair fibers (Fig 3).
Theexperimentsweredesigned to increase local IGF-1production
in hair follicles by using a UHS-KER gene promoter. This promoter
has been shown to direct a bacterial chloramphenicol acetyl trans-
ferase (CAT) gene in the skin and hair follicles of UHS-KER-CAT
transgenic mice (McNab et al, 1990). In addition, the CAT activity
could only be detected in the anagen but not telogen phase of
the hair cycle, suggesting that the UHS-KER gene contains the
controlling elements for the correct tissue and developmental expres-
sion of the reporter CAT gene in transgenic mice (McNab et al, 1990).
The observation that dual mitogenic and morphogenic functions of
IGF-1 in tissues (Sara and Hall, 1990) has led us to make UHS-KER-
IGF-1 transgenic mice and attempt to enhance proliferation and
differentiation of follicle cells by increased IGF-1 production.
Our results demonstrate that ectopic synthesis of IGF-1 in the skin
may have local effects on vibrissa growth. This can be explained by
the observation that elongated vibrissae were found at days 11–21
and consistent expression of the transgene from day 8 and days 15–
22 of mouse age. Bol et al (1997) recently found that transgenic
mice overexpressing IGF-1 in the epidermis have earlier hair follicle
development at birth and this supports the local effect of IGF-1 on
hair fiber growth. Although in situ hybridization was not performed
in our studies to determine the precise localization of IGF-1 with
reference to the follicle, expression of the transgene probably occurs
in the keratogenous zone of follicle cells based on the detection of
CAT expression in this zone in both UHS-KER-CAT transgenic
mice and sheep (McNab et al, 1990; Damak et al, 1996a).
The mechanism of action of the transgene may be due to the
paracrine effects of IGF-1 on the proliferation of epithelial cells in
the follicle bulb. IGF-1 is morphogenic and mitogenic to the skin
and acts as a morphogen in the differentiation of hair follicles
(Rudman et al, 1997). This growth factor (Messenger, 1989; Little
et al, 1994b), its receptors (IGF-1R) (Little et al, 1994a) and its
binding proteins (IGFBP) (Batch et al, 1996) are expressed in the
dermal papilla of hair follicles. In particular, the receptor was found
in the epithelial matrix cells of follicles (Hodak et al, 1996) and its
protein is differentially expressed in the matrix cells through the
hair cycle (Little et al, 1994a; Stones et al, 1994). The papilla-
derived IGF-1 may, therefore, have paracrine effects on the growth
of epithelial matrix cells. In our study, expression of the transgene
IGF-1 mRNA in the keratogenous zone may cause increased levels
of IGF-1 which diffuses to the follicle bulb, changes local production
of IGFBP, alters the interaction of transgene with IGF-1R and
stimulates growth of epithelial cells in the follicle bulb, resulting in
the observed phenotype. Although paracrine actions may be
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involved, it is also possible that overexpressed IGF-1 stimulates
local follicular metabolism and enhances cysteine uptake (Harris
et al, 1993) which flows into increased vibrissa growth.
Systemic IGF-1 mediates the endocrine effects of GH and these
effects may not extend to remote peripheral tissues such as skin or
hair follicles. Using 35S-cystine incorporation to hair fiber, we have
found that intraperitoneal injection of IGF-1 into mice has no
effect on vibrissa elongation in the anagen phase of the first hair
cycle (Su, Damak, and Bullock, unpublished data). In wool growth,
long-term systemic infusion of IGF-1 into sheep has been reported
to have no effect on fiber growth rate (Cottam et al, 1992) and
injection of recombinant bovine or ovine GH into lambs results
in no effect on wool growth despite elevated plasma IGF-1 (Spencer
et al, 1994). Further, Adams et al (1996a) demonstrate that the rate
of wool growth is independent of circulating IGF-1 as its plasma
levels are reduced while wool growth rates remain unaffected after
animals were immunized against GH-releasing hormone during
undernutrition. After a period of re-feeding, both control and
immunized animals show a similar wool growth rate, although
their plasma IGF-1 levels are different (Adams et al, 1996b),
suggesting that systemic IGF-1 is not an important determinant to
wool growth. Recent findings from our IGF-1 transgenic sheep
also support the less important role of systemic IGF-1 to wool
growth. Plasma IGF-1 levels are similar between the UHS-KER-
IGF-1 transgenic sheep and nontransgenic half-sibs while increased
wool production was found in transgenics (Su et al, 1998). Further
studies in our UHS-KER-IGF-1 transgenic mice would require to
measure the circulating level of IGF-1 and to determine its
involvement on vibrissa growth.
It is surprising that vibrissa length is increased for transgenics at
days 16–21 at the time when follicle growth proceeds to the
catagen phase. We therefore speculate that overexpressed IGF-1
may have caused a delay in the onset of catagen, although
confirmation would require histologic studies to determine the
morphogenesis and differentiation of vibrissa follicles. In addition,
a faster vibrissa growth rate at days 16–21 in both transgenic and
control animals (Table I), which may be due to the peripheral
movement of labeled club hair over this period. It is thus important
to undertake in vitro studies on the measurement of follicle growth
to determine its relationship to fiber growth. Further, it would be
important to compare the rates of DNA synthesis between trans-
genics and controls to determine their involvement in vibrissa fiber
growth during days 11–21.
The IGF-1 transgenic mice failed to show enhanced body weight
(Table I), which may suggest that ectopic synthesis of IGF-1 in
the skin did not produce a significant increase in the circulating
IGF-1 of transgenic mice. The growth-promoting actions of GH
are mediated by IGF-1 acting in both endocrine and paracrine/
autocrine fashion, while GH has a dominant endocrine influence
on plasma levels of IGF-1 and the majority of IGF-1 distributed
in tissues is from plasma (Breier and Gluckman, 1991). Expression
of the transgene in remote endocrine tissues such as skin and hair
follicles may have less influence on plasma IGF-1 levels of transgenic
mice, resulting in similar plasma levels of IGF-1 and, as a con-
sequence, similar body growth in the two groups of animals.
In summary, the results presented here support the local effects
of IGF-1 on vibrissa growth and keratinocyte-derived transgene
IGF-1 may be involved in part of the effects through paracrine
action to the epithelial matrix cells in the follicle bulb.
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